Jack Flaherty, the starting pitcher acquired by the Dodgers from the Detroit Tigers before Tuesday’s trade deadline, is widely regarded as the top pitcher moved at the deadline. His impressive 2.95 ERA and 133 strikeouts in 106.2 innings suggest he is a dominant force, supported by a 3.12 FIP and 27.5 K-BB%.
Despite Flaherty’s potential to strengthen the Dodgers’ rotation, which has struggled since early July, there are concerns about his health and effectiveness heading into the postseason and free agency. Reports from The Athletic revealed that Flaherty received back injections over a three-week period after missing a start in early July. When the Yankees withdrew their interest in Flaherty, it raised concerns among other teams, although only the Yankees and Dodgers reviewed his medicals, typically done after a trade agreement.
Flaherty has claimed to the LA Times that his back is healthy, and he feels great. He did not comment on the reports directly but stated he has felt good since before the All-Star break. Dodgers manager Dave Roberts and the team’s training staff, as well as Yankees GM Brian Cashman, have downplayed the health concerns, with Cashman noting he would have acquired Flaherty if possible.
Flaherty has posted a 1.53 ERA since receiving the injections, with notable strikeout and walk rates. However, underlying metrics like a 3.45 FIP in July suggest a bit of good luck, with a very low BABIP and high LOB%. These figures might indicate some disparity in his performance, possibly due to facing the Cleveland team, known for its strong record and low strikeout rate.